Human parvovirus B19 antibodies are less frequent among patients treated with factor IX concentrate inactivated by ultrafiltration: a report from a single Spanish institution.
Canales
M A
MA
Haemophilia Unit, Department of Haematology, Hospital La Paz, Madrid, Spain.
Pinilla
J
J
Mateos
P
P
Martínez Zapico
R
R
Alvarez
T
T
Jiménez
V M
VM
Quintana
M
M
Villar
A
A
Hernández Navarro
F
F
Magallón
M
M
D000293:Adolescent; D000328:Adult; D000368:Aged; D000914:Antibodies, Viral / Q000097:blood; D002648:Child; D002675:Child, Preschool; D020147:Coagulation Protein Disorders / Q000628:therapy; D005164:Factor IX / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D008875:Middle Aged; D010322:Parvoviridae Infections / Q000453:epidemiology / Q000209:etiology / Q000276:immunology; D016732:Parvovirus B19, Human / Q000276:immunology*; D015995:Prevalence; D013030:Spain / Q000453:epidemiology; D014462:Ultrafiltration
D000914:Antibodies, Viral; D005164:Factor IX